Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05824143 · ClinicalTrials.gov registry record · Phase 1
Open-label Trial to Evaluate the Effect Carbamazepine on Darigabat Pharmacokinetics in Healthy Adult Participants
A Phase 1 study, sponsored by Cerevel Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT05824143 is a Phase 1 study that has completed, run by Cerevel Therapeutics. The registered enrollment target is 13 participants.
The verdict
NCT05824143, a Phase 1 study, has completed, sponsored by Cerevel Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
The primary purpose of the study is to evaluate the effect of increased metabolizing enzyme (cytochrome P450 \[CYP\] 3A4) due to carbamazepine, a strong CYP3A4 inducer, on the pharmacokinetics (PK) of darigabat in healthy adult participants.
Interventions
- DRUG Carbamazepine
- DRUG Darigabat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2023-04-17 |
| Est. Completion | 2023-07-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05824143
The ClinicalTrials.gov registry entry for NCT05824143 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cerevel Therapeutics, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Carbamazepine is the first listed.
NCT05824143 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05824143 about?
NCT05824143 is a clinical study titled "Open-label Trial to Evaluate the Effect Carbamazepine on Darigabat Pharmacokinetics in Healthy Adult Participants". The primary purpose of the study is to evaluate the effect of increased metabolizing enzyme (cytochrome P450 \[CYP\] 3A4) due to carbamazepine, a strong CYP3A4 inducer, on the pharmacokinetics (PK) of darigabat in healthy adult participants.
What is the current status of trial NCT05824143?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2023-04-17. Estimated completion is 2023-07-07.
What interventions are being tested in trial NCT05824143?
The interventions under investigation include: Carbamazepine (DRUG), Darigabat (DRUG).
Who is sponsoring clinical trial NCT05824143?
This trial is sponsored by Cerevel Therapeutics, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.